We are live on ! Find out more

Kodiak Sciences

KOD

Market cap $6.31B

100.40 USD

+3.36

3.46%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

100.00

-0.40

0.4%

1 day

3.46%

5 days

17.94%

1 month

10.18%

3 months

150.94%

6 months

129.91%

Year to date

285.86%

1 year

430.38%

5 years

-14.25%

10 years

888.19%

About: Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Employees: 124

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 42.9%

Neutral 47.6%

Negative 9.5%

Zacks Investment Research

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

Kodiak's Zenkuda shows promise across three retinal diseases, with positive phase III data and a planned 2026 regulatory filing.

Can Zenkuda's Multi-Indication Potential Drive KOD Stock Higher?

Schaeffers Research

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

11 Stocks Most Likely to See a Short Squeeze Rally

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

First scientific presentation of Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration scheduled for AAO 2026. Additional presentations include Phase 3 GLOW2 data for Zenkuda in diabetic retinopathy and Phase 1b APEX data for KSI-101 in macular edema secondary to inflammation (MESI).

Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026

Top 3 Health Care Stocks That May Collapse In Q4

As of Oct. 5, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 3 Health Care Stocks That May Collapse In Q4

Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study

Kodiak Sciences NASDAQ: KOD reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuity outcomes.

Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study

24/7 Wall Street

A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.

A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?

Zacks Investment Research

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.

KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears

The Motley Fool

Why Kodiak Sciences Skyrocketed Today

Zenkuda and KSI-501 achieved their primary goals in a Phase 3 study. The global market for retinal drugs could exceed $32 billion by the end of the decade.

Why Kodiak Sciences Skyrocketed Today

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript

Proactive Investors

Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement.

Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial

See News Rankings

Price charts implemented using Lightweight Charts™